Application of NRP1 inhibitor in preparation of anti-vascular calcification medicine

The invention discloses an application of an NRP1 inhibitor in preparation of an anti-vascular calcification drug. The invention finds that the NRP1 inhibitor siRNA, EG00229, NRP1 anti-agonist 1 and ATWLPPR peptide have the effect of inhibiting the vascular calcification and the progress of the vasc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CHENG JINKUN, HUANG HUI, XIE CHEN, CHEN YANLIAN
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention discloses an application of an NRP1 inhibitor in preparation of an anti-vascular calcification drug. The invention finds that the NRP1 inhibitor siRNA, EG00229, NRP1 anti-agonist 1 and ATWLPPR peptide have the effect of inhibiting the vascular calcification and the progress of the vascular calcification, and a new thought is provided for the treatment of the vascular calcification; wherein EG00229, NRP1 antiagonist 1, ATWLPPR peptide and other small molecule drug inhibitors have good drug safety and a strong vascular calcification inhibition effect, can be dissolved in water, DMSO and ethanol, are good in stability, low in cytotoxicity and good in drug safety, can be flexibly administered through oral administration, intravenous injection and other modes, and can be used as candidate drugs for inhibiting vascular calcification; the NRP1 can also be used as a diagnostic marker of vascular calcification; the invention provides application of NRP1 as a diagnosis and treatment marker of vascular cal